- Home
- NCPL vs DRMA Comparison
NCPL vs DRMA Comparison
Compare NCPL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- DRMA
- Stock Information
- Founded
- NCPL 1984
- DRMA 2014
- Country
- NCPL United States
- DRMA United States
- Employees
- NCPL N/A
- DRMA N/A
- Industry
- NCPL Investment Managers
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- DRMA Health Care
- Exchange
- NCPL Nasdaq
- DRMA Nasdaq
- Market Cap
- NCPL 4.3M
- DRMA 4.5M
- IPO Year
- NCPL N/A
- DRMA 2021
- Fundamental
- Price
- NCPL $2.67
- DRMA $0.72
- Analyst Decision
- NCPL
- DRMA Strong Buy
- Analyst Count
- NCPL 0
- DRMA 1
- Target Price
- NCPL N/A
- DRMA $3.00
- AVG Volume (30 Days)
- NCPL 153.1K
- DRMA 108.7K
- Earning Date
- NCPL 07-28-2025
- DRMA 05-14-2025
- Dividend Yield
- NCPL N/A
- DRMA N/A
- EPS Growth
- NCPL N/A
- DRMA N/A
- EPS
- NCPL N/A
- DRMA N/A
- Revenue
- NCPL $812,612.00
- DRMA N/A
- Revenue This Year
- NCPL N/A
- DRMA N/A
- Revenue Next Year
- NCPL $101.16
- DRMA N/A
- P/E Ratio
- NCPL N/A
- DRMA N/A
- Revenue Growth
- NCPL N/A
- DRMA N/A
- 52 Week Low
- NCPL $1.41
- DRMA $0.69
- 52 Week High
- NCPL $11.90
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- NCPL 75.93
- DRMA 36.40
- Support Level
- NCPL $1.75
- DRMA $0.77
- Resistance Level
- NCPL $2.19
- DRMA $0.85
- Average True Range (ATR)
- NCPL 0.18
- DRMA 0.04
- MACD
- NCPL 0.04
- DRMA -0.00
- Stochastic Oscillator
- NCPL 89.01
- DRMA 0.00
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.